WO2002067854A3 - Manufacture of thyroid hormone tablets having consistent active moiety amounts - Google Patents

Manufacture of thyroid hormone tablets having consistent active moiety amounts Download PDF

Info

Publication number
WO2002067854A3
WO2002067854A3 PCT/US2002/004504 US0204504W WO02067854A3 WO 2002067854 A3 WO2002067854 A3 WO 2002067854A3 US 0204504 W US0204504 W US 0204504W WO 02067854 A3 WO02067854 A3 WO 02067854A3
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid hormone
manufacture
active moiety
tablets
consistent active
Prior art date
Application number
PCT/US2002/004504
Other languages
French (fr)
Other versions
WO2002067854A2 (en
Inventor
G Andrew Franz
Eliane A Strauss
Philip A Dimenna
Rocco L Gemma
Matthew Smith
Scott C Vaaler
Floyd Meredith
Original Assignee
King Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc filed Critical King Pharmaceuticals Inc
Priority to MXPA03007338A priority Critical patent/MXPA03007338A/en
Priority to CA002438907A priority patent/CA2438907A1/en
Priority to AU2002258397A priority patent/AU2002258397A1/en
Publication of WO2002067854A2 publication Critical patent/WO2002067854A2/en
Publication of WO2002067854A3 publication Critical patent/WO2002067854A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F23/00—Mixing according to the phases to be mixed, e.g. dispersing or emulsifying
    • B01F23/60—Mixing solids with solids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
    • B01F25/43—Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
    • B01F25/433—Mixing tubes wherein the shape of the tube influences the mixing, e.g. mixing tubes with varying cross-section or provided with inwardly extending profiles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/42—Static mixers in which the mixing is affected by moving the components jointly in changing directions, e.g. in tubes provided with baffles or obstructions
    • B01F25/43—Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
    • B01F25/433—Mixing tubes wherein the shape of the tube influences the mixing, e.g. mixing tubes with varying cross-section or provided with inwardly extending profiles
    • B01F25/4334—Mixers with a converging cross-section
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/80—Falling particle mixers, e.g. with repeated agitation along a vertical axis
    • B01F25/82—Falling particle mixers, e.g. with repeated agitation along a vertical axis uniting flows of material taken from different parts of a receptacle or from a set of different receptacles

Abstract

An apparatus for the transport of thyroid hormone drug formulations from a blender (100) to a tablet press using mass flow of the formulation in order to maintain consistent tablet compositions during manufacture of the tablets.
PCT/US2002/004504 2001-02-15 2002-02-15 Manufacture of thyroid hormone tablets having consistent active moiety amounts WO2002067854A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MXPA03007338A MXPA03007338A (en) 2001-02-15 2002-02-15 Manufacture of thyroid hormone tablets having consistent active moiety amounts.
CA002438907A CA2438907A1 (en) 2001-02-15 2002-02-15 Manufacture of thyroid hormone tablets having consistent active moiety amounts
AU2002258397A AU2002258397A1 (en) 2001-02-15 2002-02-15 Manufacture of thyroid hormone tablets having consistent active moiety amounts

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26899801P 2001-02-15 2001-02-15
US60/268,998 2001-02-15

Publications (2)

Publication Number Publication Date
WO2002067854A2 WO2002067854A2 (en) 2002-09-06
WO2002067854A3 true WO2002067854A3 (en) 2004-04-15

Family

ID=23025405

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/004504 WO2002067854A2 (en) 2001-02-15 2002-02-15 Manufacture of thyroid hormone tablets having consistent active moiety amounts

Country Status (4)

Country Link
AU (1) AU2002258397A1 (en)
CA (1) CA2438907A1 (en)
MX (1) MXPA03007338A (en)
WO (1) WO2002067854A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
SI2234631T1 (en) 2007-12-18 2013-02-28 Athera Biotechnologies Ab Compounds and methods for the treatment of vascular disease
EP3013571B1 (en) 2013-06-27 2023-06-07 GEA Process Engineering nv Method for continuous production of tablets, tabletting system for carrying out the method, and use of the tabletting system for the production of tablets of at least two ingredients containing particles with a significant difference in particle size

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099001A (en) * 1989-12-28 1992-03-24 Nepera, Inc. Process for the production of thyroglobulin
US5407339A (en) * 1993-09-27 1995-04-18 Vector Corporation Triturate tablet machine
US6227836B1 (en) * 1994-07-07 2001-05-08 Sankyo Seisakusho Co & Eisai Co., Ltd. Apparatus for manufacturing tablets
US6410587B1 (en) * 1997-04-11 2002-06-25 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099001A (en) * 1989-12-28 1992-03-24 Nepera, Inc. Process for the production of thyroglobulin
US5407339A (en) * 1993-09-27 1995-04-18 Vector Corporation Triturate tablet machine
US6227836B1 (en) * 1994-07-07 2001-05-08 Sankyo Seisakusho Co & Eisai Co., Ltd. Apparatus for manufacturing tablets
US6410587B1 (en) * 1997-04-11 2002-06-25 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies

Also Published As

Publication number Publication date
MXPA03007338A (en) 2005-06-06
AU2002258397A1 (en) 2002-09-12
WO2002067854A2 (en) 2002-09-06
CA2438907A1 (en) 2002-09-06
AU2002258397A8 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
LT2000064A (en) Flash-melt oral dosage formulation
WO2006078593A3 (en) Direct compression formulation and process
HK1096034A1 (en) A solid dosage form comprising a fibrate
HK1046620A1 (en) Process for manufacturing a pharmaceutical chewinggum
UA84266C2 (en) Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyroolidon as excipient, processes for the preparation and use thereof
IS8885A (en) Oral solid formulation containing S1P receptor agonist and sugar alcohol
MY127350A (en) Flash-melt oral dose formulations
DK0673245T3 (en) Pharmaceutical shower composition containing ibuprofen and process for its preparation.
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
CA2366679A1 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
WO2002024203A3 (en) Controlled release formulations for oral administration
CA2445519A1 (en) Method for manufacturing a low dose pharmaceutical composition
HK1067299A1 (en) Pharmaceutical compositions containing terbinafineand use thereof
HU9302971D0 (en) Chewable antacid preparations
WO2005115346A3 (en) Pharmaceutical composition containing risperidone
HUP0204202A3 (en) Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it
SI1586320T1 (en) Cytisine containing solid dosage form
WO2002067854A3 (en) Manufacture of thyroid hormone tablets having consistent active moiety amounts
WO2003028624A3 (en) Levothyroxine compositions and methods
WO1999047172A3 (en) Oral pharmaceutical compositions to be taken without liquids, which contain inclusion complexes
CA2406269A1 (en) Process for drying amoxicillin
WO2003035043A3 (en) Pharmaceutical formulation comprising more than 15% tamoxifen
WO2004014318A3 (en) Levothyroxine compositions and methods
EP1513512A4 (en) Soluble stable pharmaceutical composition for the administration of hiv protease inhibitors and a process for the preparation of concentrated pharmaceutical compositions for the administration of hiv protease inhibitors.
WO2002041875A3 (en) Method for producing readily soluble medicament formulations and corresponding formulations

Legal Events

Date Code Title Description
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/007338

Country of ref document: MX

Ref document number: 2438907

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP